NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $3.00 -0.08 (-2.44%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Iovance Biotherapeutics Stock (NASDAQ:IOVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IOVA alerts:Sign Up Key Stats Today's Range$2.97▼$3.0850-Day Range$2.85▼$5.7852-Week Range$2.70▼$14.23Volume987,119 shsAverage Volume9.68 million shsMarket Capitalization$981.99 millionP/E RatioN/ADividend YieldN/APrice Target$18.56Consensus RatingModerate Buy Company OverviewIovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More… Remove Ads Iovance Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreIOVA MarketRank™: Iovance Biotherapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 138th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Iovance Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.32% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 11.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.08 Percentage of Shares Shorted28.32% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 11.72%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.56 News SentimentIovance Biotherapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Iovance Biotherapeutics this week, compared to 7 articles on an average week.Search InterestOnly 34 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows20 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Stock News HeadlinesIs Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17 at 3:43 AM | msn.comBarclays Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock PriceApril 16 at 2:33 AM | americanbankingnews.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 17, 2025 | Colonial Metals (Ad)Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)April 16 at 1:19 AM | markets.businessinsider.comIovance Biotherapeutics price target lowered to $5 from $22 at BarclaysApril 15 at 8:17 PM | markets.businessinsider.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $20.25 Average PT from BrokeragesApril 15 at 1:46 AM | americanbankingnews.comIs Iovance Biotherapeutics a Millionaire-Maker?April 14 at 10:05 AM | fool.comIovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comSee More Headlines IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $7.40 at the start of the year. Since then, IOVA stock has decreased by 58.5% and is now trading at $3.07. View the best growth stocks for 2025 here. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). The biotechnology company earned $73.69 million during the quarter, compared to analysts' expectations of $72.17 million. Iovance Biotherapeutics had a negative trailing twelve-month return on equity of 58.43% and a negative net margin of 451.25%. Read the conference call transcript. Who are Iovance Biotherapeutics' major shareholders? Top institutional investors of Iovance Biotherapeutics include Hennion & Walsh Asset Management Inc. (0.11%), SG Americas Securities LLC (0.04%), Assenagon Asset Management S.A. (0.01%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes, Ryan D Maynard and Frederick G Vogt. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings2/27/2025Today4/17/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOVA CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees500Year Founded2013Price Target and Rating Average Stock Price Target$18.56 High Stock Price Target$32.00 Low Stock Price Target$5.00 Potential Upside/Downside+504.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-451.25% Pretax Margin-458.01% Return on Equity-58.43% Return on Assets-45.48% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio3.90 Sales & Book Value Annual Sales$164.07 million Price / Sales6.14 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book1.35Miscellaneous Outstanding Shares327,877,000Free Float267,902,000Market Cap$1.01 billion OptionableOptionable Beta1.05 Social Links Free Today: Your Guide to Smarter Options TradesLearn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.Get This Free Report This page (NASDAQ:IOVA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
